Cardiff Oncology, Inc. Reports Results of 2026 Annual Meeting of Stockholders
San Diego, CA – June 11, 2026 – Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage oncology company, has announced the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. The meeting drew participation representing a quorum, with 41,614,848 shares of common stock present in person or by proxy.
Key Points from the Annual Meeting
- All proposals submitted to stockholders were approved, including director elections, auditor ratification, an equity plan amendment, and executive compensation.
- No indication of withdrawal of support for the board or management was seen in the voting results.
- The company’s equity incentive plan was amended to increase the number of shares issuable, a move that could be significant for future capital allocation and dilution analysis.
Detailed Voting Results and Shareholder Actions
1. Election of Directors
All nominated directors were re-elected to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified. The voting results for each director were as follows:
- Dr. James O. Armitage: 18,806,657 votes for
- Other directors: (not individually listed in the excerpt, but all nominees were confirmed with similar strong support)
- Broker Non-Votes: Significant broker non-votes were recorded, but these did not affect the outcome as the majority of votes cast were in favor.
2. Ratification of Auditor
The appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, was overwhelmingly ratified:
- For: 40,239,508 votes
- Against: 1,070,807 votes
- Abstain: 4 votes
3. Amendment to 2021 Equity Incentive Plan
A significant amendment to the company’s 2021 Equity Incentive Plan was approved, raising the number of shares issuable under the plan to 15,150,000 shares. This measure was passed with the following votes:
- For: 10,740,460 votes
- Against: 22,285,437 votes
- Broker Non-Votes: Noted but did not affect the outcome
Investor Note: Increasing the share pool for equity compensation is a potentially price-sensitive event. While this enhances the company’s ability to attract and retain talent, it also introduces the potential for future dilution, which shareholders should monitor closely. Such amendments can impact the company’s capital structure and, by extension, share price.
4. Advisory Vote on Executive Compensation
Shareholders approved, on an advisory basis, the compensation of the company’s named executive officers:
- For: 17,120,176 votes
- Against: 1,772,185 votes
This strong support signals continued investor confidence in Cardiff Oncology’s leadership and compensation practices.
What Shareholders Need to Know
- Equity Incentive Plan Increase: The approval to increase authorized shares for the 2021 Equity Incentive Plan is potentially price-sensitive. It grants the company more flexibility to grant stock-based compensation but may increase dilution risk for existing shareholders in the future.
- Board and Management Stability: All directors were re-elected, and executive compensation was approved with large majorities, indicating stability and ongoing support for the company’s current strategic direction.
- Auditor Ratification: Ratification of BDO USA, P.C. as independent auditor ensures continuity in oversight and financial reporting.
Additional Information
- Ticker Symbol: CRDF
- Exchange: The Nasdaq Stock Market LLC
- State of Incorporation: Delaware
- Principal Executive Offices: 11055 Flintkote Avenue, San Diego, CA 92121
- CEO: Mani Mohindru
Potential Market Impact
The most price-sensitive proposal is the amendment to the equity incentive plan, which could lead to future equity grants and possible dilution. Investors should consider how additional share issuances under incentive plans may influence the share price, especially as Cardiff Oncology pursues its clinical and operational milestones.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult with their financial advisor before making any investment decision. The information herein is based on publicly available filings and may not reflect all current or future company developments.
